



## Review Article

### Kawasaki Disease as the Immune-Mediated Echo of a Viral Infection

Donato Rigante<sup>1,2</sup>.

<sup>1</sup> Department of Life Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

<sup>2</sup> Università Cattolica Sacro Cuore, Rome, Italy.

**Competing interests:** The authors declare no conflict of Interest.

**Abstract.** Although the etiology of Kawasaki disease (KD) remains elusive, the available evidence indicates that the *primum movens* may be a dysregulated immune response to various microbial agents, leading to cytokine cascade and endothelial cell activation in patients with KD. Documented infections by different viruses in many individual cases have been largely reported and are discussed herein, but attempts to demonstrate their causative role in the distinctive KD scenario and KD epidemiological features have been disappointing. To date, no definite link has been irrefutably found between a single infection and KD.

**Keywords:** Kawasaki disease; Viral infection; COVID-19; Child; Personalized medicine.

**Citation:** Rigante D. Kawasaki disease as the immune-mediated echo of a viral infection. *Mediterr J Hematol Infect Dis* 2020, 12(1): e2020039, DOI: <http://dx.doi.org/10.4084/MJHID.2020.039>

**Published:** July 1, 2020

**Received:** May 21, 2020

**Accepted:** June 17, 2020

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by-nc/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Correspondence to: Donato Rigante, MD, PhD, Department of Life Sciences and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Sacro Cuore, Rome, Largo A. Gemelli 8, 00168 Rome, Italy. Tel: +39 06 30154475. Fax +39 06 3383211. E-mail: [donato.rigante@unicatt.it](mailto:donato.rigante@unicatt.it)

**The History of Kawasaki Disease.** Almost 60 years ago, dr. Tomisaku Kawasaki noted, for the first time, a strange association of symptoms in a 4-year-old boy who was hospitalized at the Chiba University. The child had prolonged high fever, conjunctivitis, a widespread rash all over the body, and a bright-red tongue. However, he could not explain that disease, thinking to an allergy or any infectious diseases. Antibiotics were ineffective in treating that boy's symptoms, which subsided only after two weeks, also revealing specific desquamation of the fingers and toes. One year later, another child was hospitalized with those same symptoms, and dr. Kawasaki convinced himself that a mysterious illness could affect children. In 1967 he published a 44-page report of all hospitalized patients having that illness (that he named "acute febrile mucocutaneous lymph node syndrome") in the Japanese journal "Arerugi", usually dedicated to allergology, which was based on a diligent 6-year observation of 50 patients.<sup>1</sup> The eponym of Kawasaki disease (KD) was coined later, when an

international journal offered a large amount of space to the description of this illness.<sup>2</sup> With some cases of sudden death occurring after an apparent resolution of KD, the issue started to gain more and more attention by the scientific community, and pediatric textbooks started to report on this condition.

**A Systemic Vasculitis is the Key to Explain Kawasaki Disease.** In plain terms, KD is a systemic vasculitis that mainly and typically occurs in infants and children less than five years: the most ominous complication of patients with KD is the occurrence of coronary artery abnormalities (CAA).<sup>3</sup> For this reason, KD is actually the leading cause of acquired pediatric heart disease in the developed world.<sup>4</sup> Many reports found that coronary arteritis occurred at the highest incidence, but that vasculitis developed at various sites throughout the body. Vascular lesions of KD may start in the tunica interna and externa of medium-sized muscular arteries, such as the coronary arteries, but also in arterioles, venules and

capillaries, while inflammation disseminates to large arteries including the coronary arteries.<sup>5,6</sup> The media of affected vessels demonstrates edematous dissociation of the smooth muscle cells, while endothelial cell swelling and subendothelial edema are seen. An influx of neutrophils can be observed in the early stages of KD, with a rapid transition to large mononuclear cells in concert with lymphocytes and IgA plasma cells. Destruction of the internal elastic lamina and an eventual fibroblast proliferation can occur later. This active inflammation is replaced over several weeks to months by progressive fibrosis, with scar formation and remodeling.<sup>7</sup>

**The Clinical Chameleon of Kawasaki Disease.** The classic diagnosis of KD has been historically based on the presence of 5 days of fever and a typical constellation of nonspecific clinical signs described in 1967 by Dr. Kawasaki: upholding the diagnosis of KD requires that highly swinging fever is combined with at least 4 out of 5 "main" clinical features: [a] bilateral non-exudative conjunctivitis, [b] unilateral cervical lymphadenopathy, [c] polymorphous rash, [d] changes in the extremities (mainly in the form of angioedema) or in the perineal region (an early-onset desquamating rash) and [e] changes in the lips and/or oral cavity (dry fissured or reddened lips with a strawberry-like tongue).<sup>8</sup> Although the clinical clues of KD are easily recognizable, its underlying mechanisms are under deep investigation and remain poorly understood. Treatment of KD requires intravenous immunoglobulin (IVIG) and aspirin during the first ten days of illness, and its ultimate goal is avoiding the occurrence of CAA.<sup>9</sup> Mostly in the case of resistance to IVIG, inflammatory cells reach the vasa vasorum of coronary arteries with the risk of fragmentation of the internal lamina and damage to the media, resulting in the formation of CAA.<sup>10</sup> Higher values of C-reactive protein and younger age at onset are crucial points in determining respectively a failure in response to IVIG and a higher risk that the disease could be complicated by CAA.<sup>11</sup> Early ascertainment of non-responders to IVIG who might require additional therapies reducing the development of CAA is still a challenge.<sup>12</sup> With improved treatment methods and different drugs useful for refractory cases, the mortality rate of KD has dropped dramatically in recent years. However, despite increased awareness, the number of patients with KD presenting with incomplete or atypical features is increasing across the world. Incomplete cases of KD are characterized by less than four main clinical signs and atypical ones by a broad range of unusual clinical features, including aseptic meningitis, peripheral facial nerve palsy, liver impairment with jaundice, gallbladder hydrops, pneumonia-like disease, and even macrophage activation syndrome.<sup>13,14</sup>

**Different Potential Causes, One Resulting Disease.** Despite extensive research, the etiology of KD is far to be unraveled, and no single pathognomonic clinical or laboratory finding for diagnosis has been identified. Indeed, the occurrence of KD in epidemics, as shown by nationwide epidemiologic surveys conducted with biennial frequency since 1970, reveals a potential relationship of KD with an infectious disease. A number of infectious agents, both bacterial and viral, have been isolated from patients with KD through the years,<sup>15</sup> but also non-infectious triggers are presumed to cause the disease.<sup>16</sup> Further KD characteristics such as high-grade fever, elevated acute-phase reactants, and elevated white blood cell count strongly suggest an infectious cause, and in particular, some characteristics may suggest a viral etiology, such as the self-limited course of KD, skin rash and conjunctivitis. A host of reports have clarified the distinct seasonality of KD in geographically distinct regions of the northern hemisphere, revealing that various triggers may be operating at different times of the year in various geospatial clustering of KD cases:<sup>17</sup> the seasonality of KD, with winter peaks in Japan and winter-spring predominance in the USA or in many other temperate areas, is highly suggestive of a viral etiology.<sup>18</sup> Shimizu et al. found a seasonal effect also on the response to IVIG treatment, with more patients manifesting resistance to IVIG in the warm seasons from May to October, but no differences in the general outcome of CAA.<sup>19</sup> Several epidemiological studies have also demonstrated that KD is frequently associated with a previous respiratory illness; however, no differences have been found in children stratified according to positive or negative respiratory viral testing; in fact, a positive test for respiratory viruses at the time of presentation should not be used to exclude the diagnosis of KD.<sup>20</sup>

**A Viral Infection to Switch on Kawasaki Disease.** Searching for papers dedicated to KD and published in the last 35 years through PubMed (matching the terms "KD" and "virus" or "viral infection"), a list of viral agents hypothetically associated with KD can be drawn (see **Table 1**). Viral respiratory infections have been commonly found at the diagnosis of KD,<sup>21</sup> but they do not seem to affect patients' response to IVIG or influence the overall outcome.<sup>22</sup> The oldest reports date back to 1983 when rotavirus was found in the feces of children with KD<sup>23</sup> and to 1985 when parainfluenza virus and adenovirus were encountered.<sup>24,25</sup> A molecular-based adenovirus detection is relatively frequent in KD patients but should be interpreted with caution.<sup>26</sup> Indeed, 24 out of 25 children with adenovirus disease mimicking features of KD had a higher viral burden compared to those with KD and incidental adenovirus detection.<sup>27</sup> Anecdotal reports had been associated KD to human herpesvirus-6,

**Table 1.** Viral agents associated with Kawasaki disease.

<i>Viral agent</i>	<i>References</i>	<i>Year</i>	<i>First authors</i>	<i>Modality of study</i>
Rotavirus	23	1983	Matsuno	Hemagglutination on feces
Parainfluenza virus	24	1985	Johnson	Culture on pharyngeal swab
Adenovirus	25	1985	Embil	Autoptic result
Adenovirus	26,27	2013, 2016	Jaggi, Song	RT-PCR
Herpesvirus 6	28,29	1989, 1992	Okano, Hagiwara	Serum antibodies
Parvovirus B19	30,45	1995, 2019	Holm, Maggio	Serum antibodies
Cytomegalovirus	31	2008	Usta Guc	Serum antibodies
Epstein-Barr virus	32	1994	Kanegane	RT-PCR
Epstein-Barr virus	33,44	1990, 2019	Kikuta, Maggio	Serum antibodies
Measles virus	34	2000	Kuijpers	Clinical assessment
Herpes virus	35	2002	Shingadia	RT-PCR
Varicella-zoster virus	36	2004	Lee	Clinical assessment
Influenza virus	37,38,46	2011, 2015, 2019	Joshi, Huang, Wang	RT-PCR
Coxsackie B3 virus	39	2012	Rigante	Serum antibodies
Bocavirus	40,41,42,57	2007, 2011, 2014, 2019	Catalano-Pons, Santos, Bajolle, L'Huillier	RT-PCR
Torque teno virus 7	42	2018	Thissen	RT-PCR
New Haven coronavirus	48	2005	Esper	RT-PCR
Coronavirus NL63	49	2006	Dominguez	RT-PCR
Coronavirus 229E	50	2014	Shirato	Serum antibodies
Coronavirus	47	2014	Chang	RT-PCR
New coronavirus SARS-CoV-2	51,52,53,54	2020	Jones, Rivera-Figueroa, Verdoni, Dufort	RT-PCR

parvovirus B19 and cytomegalovirus.<sup>28-31</sup> However, the highest number of KD reports has been related to Epstein-Barr virus,<sup>32,33</sup> while KD cases with a concomitant infection caused by measles virus,<sup>34</sup> herpesvirus,<sup>35</sup> varicella-zoster virus,<sup>36</sup> influenza virus,<sup>37,38</sup> coxsackie virus,<sup>39</sup> and bocavirus are mostly isolated reports.<sup>40</sup> In particular for bocavirus, its nucleic acid was found in the nasopharyngeal, serum and stool samples from 5/16 (31.2%) patients with KD by reverse transcriptase-polymerase chain reaction (RT-PCR).<sup>41</sup> A prospective study by Bajolle et al. revealed that bocavirus was present in the serum of 3/32 (9%) and in the nasopharyngeal aspirate of 7/32 (21.8%) patients with KD, who probably had a previous bocavirus infection heralding KD.<sup>42</sup> Metagenomic sequencing and PCR detected torque teno virus 7 in only 2/11 (18%) patients with KD prospectively evaluated for one year,<sup>43</sup> while the most recent reports have highlighted the association of KD with Epstein-Barr virus,<sup>44</sup> parvovirus B19<sup>45</sup> and influenza virus.<sup>46</sup>

**The Outbreak of the New Coronavirus and Kawasaki Disease.** The latest outbreak of the new coronavirus (HCoV) infection (named SARS-CoV-2) and the resulting pandemic threat to health worldwide has required strict social containment measures since February 2020, but has also spread the suspicion that

this peculiar infection might trigger KD. As a matter of fact, HCoV has been associated with many reports of KD in the past: for instance, in a prospective case-controlled study among Taiwanese children it was isolated in 7.1% of cases.<sup>47</sup> In 2005 Esper et al. identified a novel human HCoV, named "New Haven," in the respiratory secretions from 8/11 children with KD.<sup>48</sup> However, in Denver (Colorado, USA) the prevalence of HCoV-NL63 infection was not higher in KD patients compared with non-KD controls.<sup>49</sup> The contribution of HCoV-229E infection in the development of KD was also brought in question by Shirato et al., who used immunofluorescence testing to detect virus-neutralizing antibodies in 15 patients with KD before IVIG treatment.<sup>50</sup> The first case of KD associated with a concomitant SARS-CoV-2 infection was a 6-month infant hospitalized in Palo Alto (California, USA). However, the clinical significance of patient's positive testing remained unclear in the setting of KD.<sup>51</sup> Furthermore, a 5-year-old Afro-American boy was found to have KD-related signs in Jackson (Mississippi, USA) in combination with severe acute respiratory distress and shock syndrome, referred to SARS-CoV-2 infection detected via RT-PCR from his nasopharyngeal swab.<sup>52</sup> In April 2020, Verdoni et al. reported a 30-fold increased incidence of KD-like syndrome in children living in the Bergamo province of Italy, after the SARS-CoV-2 epidemic began in that same area, also showing

higher rates of heart involvement and general features of macrophage activation or shock syndrome. The evidence of contact with the virus was confirmed by the presence of antibodies against SARS-CoV-2 in 8 out of 10 reported patients.<sup>53</sup> This study had the limitation of being based on a small case series, but suggested in-depth genetic analysis to investigate the potential susceptibility to KD after a triggering effect of SARS-CoV-2.

More recently, in the New York State (USA) during the period March-May 2020, a SARS-CoV-2-related multisystem inflammatory syndrome has been found in 95 patients younger than 21 years of all ethnic backgrounds: such patients presented an inflammatory vasculopathy showing some similarities to KD and toxic shock syndrome, and in particular nearly half of children 0 to 5 years, but only 12% of the adolescents 13 to 20 years of age had a discharge diagnosis of KD or atypical KD.<sup>54</sup> This study had the limitation of a presumed underestimation, possibly due to mild cases that did not require hospitalization.

**The Evidence about Viral Contributors to Kawasaki Disease.** Ultimately, viruses may be confounding bystanders in many descriptions of KD. However, intracytoplasmic inclusion bodies sharing morphologic features among several different RNA viral families have been found in autoptic tissues of patients deceased for KD.<sup>55</sup> Rowley et al. speculated that the development of KD could follow ubiquitous RNA viruses causing an asymptomatic infection or a very mild disease in the vast majority of children, but specifically "KD" in a subset of genetically selected people.<sup>56</sup> In addition, a pilot study investigating KD pathogenesis revealed specific viral signatures in 4/7 patients with KD via high-throughput sequencing on blood specimens, although 2 were corresponding to their vaccinal history (oral poliovirus and measles/mumps/rubella vaccine) and 2 to bocavirus and rhinovirus, which could suggest a temporal association with the disease.<sup>57</sup> Different studies have also found that an imbalance in the gut microbiota might interfere with the normal function of innate and adaptive

immunity, and that variable microbiota interactions with environmental factors, mainly infectious agents, might drive the development of KD in a genetically susceptible child.<sup>58</sup> However, to date, no definite link has been irrefutably found between any viral agents and KD.

**Conclusive Remarks.** More than half a century after its discovery, it is frustrating to admit that KD is believed to be triggered by an infection, but that its direct unequivocal cause is unclear. Besides, at the age of 95, dr. Kawasaki remains very active and continues to support families with KD children through different nonprofit organizations. New theories about KD hypothesize that the disorder might be conceived as an autoinflammatory condition,<sup>59</sup> in which inflammation explodes without any involvement of autoimmune pathways and any sound relationship with microbial agents.<sup>60-62</sup> Although KD causal factors are still elusive, the available evidence indicates that the *primum movens* may be a dysregulation of immune responses to various infectious agents, i.e., a kind of immune-mediated "echo" induced also by a viral infection. Even if several data might suggest that KD is an infection-related clinical syndrome, which can develop only in children with a predisposing genetic background, our knowledge on both the infectious agents involved and genetic characteristics of susceptible children remains poor. Understanding the molecular players responsible for dysregulation of the immune response in KD will foster the development of improved predictive tools and a more rational use of therapeutic agents to decrease the risk of CAA in all children with KD.

**In Memoriam.** On June 5, 2020 dr. Tomisaku Kawasaki passed away at the age of 95: the news had a profound impact on many clinicians who dedicated their professional lives studying Kawasaki disease. He was a true model to all pediatricians, not only with regard to his clinical acumen but especially concerning his vibrant humanity. This article is sincerely dedicated to the memory of Tomisaku Kawasaki.

## References:

1. Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. *Arerugi* 1967; 16:178-222. PMID: 6062087
2. Kawasaki T, Kosaki F, Okawa S, et al. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. *Pediatrics* 1974;54:271-6. PMID: 4153258
3. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. *Pediatrics* 2004;114:1708-33. <https://doi.org/10.1542/peds.2004-2182> PMID:15574639
4. Falcini F, Capannini S, Rigante D. Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas. *Pediatr Rheumatol Online J* 2011;9:17 <https://doi.org/10.1186/1546-0096-9-17> PMID:21774801 PMCID:PMC3163180
5. Amano S, Hazama F, Kubagawa H, et al. General pathology of Kawasaki disease on the morphological alterations corresponding to the clinical manifestations. *Acta Pathol Jpn* 1980;30:681-94. <https://doi.org/10.1111/j.1440-1827.1980.tb00966.x> PMID: 7446109
6. Hamashima Y. Kawasaki disease. *Heart Vessels Suppl* 1985;1:271-6. <https://doi.org/10.1007/BF02072407> PMID:3843587
7. Suzuki A, Miyagawa-Tomita S, Komatsu K, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study. *Circulation* 2000;101:2935-41. <https://doi.org/10.1161/01.CIR.101.25.2935> PMID:10869266

8. De Rosa G, Pardeo M, Rigante D. Current recommendations for the pharmacologic therapy in Kawasaki syndrome and management of its cardiovascular complications. *Eur Rev Med Pharmacol Sci* 2007;11:301-8. PMID: 18074939
9. Marchesi A, Tarissi De Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of the Italian Society of Pediatrics, part I - definition, epidemiology, etiopathogenesis, clinical expression and management of the acute phase. *Ital J Pediatr* 2018;44(1):102. <https://doi.org/10.1186/s13052-018-0536-3> PMID:30157897 PMCid:PMC6116535
10. Marchesi A, Tarissi De Jacobis I, Rigante D, et al. Kawasaki disease: guidelines of Italian Society of Pediatrics, part II - treatment of resistant forms and cardiovascular complications, follow-up, lifestyle and prevention of cardiovascular risks. *Ital J Pediatr* 2018;44(1):103. <https://doi.org/10.1186/s13052-018-0529-2> PMID:30157893 PMCid:PMC6116479
11. Rigante D, Valentini P, Rizzo D, et al. Responsiveness to intravenous immunoglobulins and occurrence of coronary artery abnormalities in a single-center cohort of Italian patients with Kawasaki syndrome. *Rheumatol Int* 2010;30:841-6. <https://doi.org/10.1007/s00296-009-1337-1> PMID:20049445
12. Rigante D, Andreozzi L, Fastigi M, et al. Critical overview of the risk scoring systems to predict non-responsiveness to intravenous immunoglobulin in Kawasaki syndrome. *Int J Mol Sci* 2016;17:278. <https://doi.org/10.3390/ijms17030278> PMID:26927060 PMCid:PMC4813142
13. Falcini F, Ozen S, Magni-Manzoni S, et al. Discrimination between incomplete and atypical Kawasaki syndrome versus other febrile diseases in childhood: results from an international registry-based study. *Clin Exp Rheumatol* 2012;30:799-804.
14. Stabile A, Bertoni B, Ansuini V, et al. The clinical spectrum and treatment options of macrophage activation syndrome in the pediatric age. *Eur Rev Med Pharmacol Sci* 2006;10:53-9.
15. Principi N, Rigante D, Esposito S. The role of infection in Kawasaki syndrome. *J Infect* 2013;67:1-10 <https://doi.org/10.1016/j.jinf.2013.04.004> PMID:23603251 PMCid:PMC7132405
16. Rigante D, Tarantino G, Valentini P. Non-infectious makers of Kawasaki syndrome: tangible or elusive triggers? *Immunol Res* 2016;64:51-4. <https://doi.org/10.1007/s12026-015-8679-4> PMID:26232895
17. Rowley AH, Shulman ST. The epidemiology and pathogenesis of Kawasaki disease. *Front Pediatr*. 2018;6:374. <https://doi.org/10.3389/fped.2018.00374> PMID:30619784 PMCid:PMC6298241
18. Burns JC, Herzog L, Fabri O, et al. Seasonality of Kawasaki disease: a global perspective. *PLoS One* 2013;8(9):e74529. <https://doi.org/10.1371/journal.pone.0074529> PMID:24058585 PMCid:PMC3776809
19. Shimizu D, Hoshina T, Kawamura M, et al. Seasonality in clinical courses of Kawasaki disease. *Arch Dis Child* 2019;104:694-6. <https://doi.org/10.1136/archdischild-2018-315267> PMID:30413486
20. Turnier JL, Anderson MS, Heizer HR, et al. Concurrent respiratory viral infections in children with Kawasaki disease. *Pediatrics*. 2015;136:e609-14. <https://doi.org/10.1542/peds.2015-0950> PMID:26304824
21. Jordan-Villegas A, Chang ML, Ramilo O, et al. Concomitant respiratory viral infections in children with Kawasaki disease. *Pediatr Infect Dis J* 2010;29:770-2. <https://doi.org/10.1097/INF.0b013e3181dba70b> PMID:20354462 PMCid:PMC2927322
22. Benseler SM, McCrindle BW, Silverman ED, et al. Infections and Kawasaki disease: implications for coronary artery outcome. *Pediatrics* 2005;116:e760-6. <https://doi.org/10.1542/peds.2005-0559> PMID:16322132
23. Matsuno S, Utagawa E, Sugiura A. Association of rotavirus infection with Kawasaki syndrome. *J Infect Dis* 1983;148:177. <https://doi.org/10.1093/infdis/148.1.177> PMID:6309994
24. Johnson D, Azimi P. Kawasaki disease associated with Klebsiella pneumoniae bacteremia and parainfluenza type 3 virus infection. *Pediatr Infect Dis J* 1985;4:100-3. <https://doi.org/10.1097/00006454-198501000-00024> PMID:2982131
25. Embil JA, McFarlane ES, Murphy DM, et al. Adenovirus type 2 isolated from a patient with fatal Kawasaki disease. *Can Med Assoc J* 1985;132:1400. PMID: 4005729
26. Jaggi P, Kajon AE, Mejias A, et al. Human adenovirus infection in Kawasaki disease: a confounding bystander? *Clin Infect Dis* 2013;56:58-64. <https://doi.org/10.1093/cid/cis807> PMID:23011145 PMCid:PMC3732045
27. Song E, Kajon AE, Wang H, et al. Clinical and virologic characteristics may aid distinction of acute adenovirus disease from Kawasaki disease with incidental adenovirus detection. *J Pediatr* 2016;170:325-30. <https://doi.org/10.1016/j.jpeds.2015.11.021> PMID:26707621
28. Okano M, Luka J, Thiele GM, et al. Human herpesvirus 6 infection and Kawasaki disease. *J Clin Microbiol* 1989;27:2379-80. <https://doi.org/10.1128/JCM.27.10.2379-2380.1989> PMID:2555393 PMCid:PMC2670229
29. Hagiwara K, Komura H, Kishi F, Kaji T, Yoshida T. Isolation of human herpesvirus-6 from an infant with Kawasaki disease. *Eur J Pediatr* 1992;151:867-8. <https://doi.org/10.1007/BF01957946> PMID:1334835
30. Holm JM, Hansen LK, Oxhøj H. Kawasaki disease associated with parvovirus B19 infection. *Eur J Pediatr* 1995;154:633-4. <https://doi.org/10.1007/BF02079066> PMID:7588963
31. Usta Guç B, Cengiz N, Yildirim SV, et al. Cytomegalovirus infection in a patient with atypical Kawasaki disease. *Rheumatol Int* 2008;28:387-9. <https://doi.org/10.1007/s00296-007-0440-4> PMID:17717671 PMCid:PMC7079931
32. Kanegane H, Tsuji T, Seki H, et al. Kawasaki disease with a concomitant primary Epstein-Barr virus infection. *Acta Paediatr Jpn* 1994;36:713-6. <https://doi.org/10.1111/j.1442-200X.1994.tb03277.x> PMID:7871990
33. Kikuta H, Matsumoto S, Yanase Y, et al. Recurrence of Kawasaki disease and Epstein-Barr virus infection. *J Infect Dis* 1990;162:1215. <https://doi.org/10.1093/infdis/162.5.1215> PMID:2172398
34. Kuijpers TW, Herweijer TJ, Scholvinck L, et al. Kawasaki disease associated with measles virus infection in a monozygotic twin. *Pediatr Infect Dis J* 2000;19:350-3. <https://doi.org/10.1097/00006454-200004000-00018> PMID:10783028
35. Shingadia D, Bose A, Booy R. Could a herpesvirus be the cause of Kawasaki disease? *Lancet Infect Dis* 2002;2:310-3. [https://doi.org/10.1016/S1473-3099\(02\)00265-7](https://doi.org/10.1016/S1473-3099(02)00265-7)
36. Lee DH, Huang HP. Kawasaki disease associated with chickenpox: report of two sibling cases. *Acta Paediatr Taiwan* 2004;45:94-6.
37. Joshi AV, Jones KD, Buckley AM, et al. Kawasaki disease coincident with influenza A H1N1/09 infection. *Pediatr Int* 2011;53:e1-2 <https://doi.org/10.1111/j.1442-200X.2010.03280.x> PMID:21342333 PMCid:PMC7167673
38. Huang X, Huang P, Zhang L, et al. Influenza infection and Kawasaki disease. *Rev Soc Bras Med Trop* 2015;48:243-8. <https://doi.org/10.1590/0037-8682-0091-2015> PMID:26108000
39. Rigante D, Cantarini L, Piastra M, et al. Kawasaki syndrome and concurrent Coxsackie-virus B3 infection. *Rheumatol Int* 2012;32:4037-40. <https://doi.org/10.1007/s00296-010-1613-0> PMID:21052673 PMCid:PMC7080020
40. Catalano-Pons C, Giraud C, Rozenberg F, et al. Detection of human bocavirus in children with Kawasaki disease. *Clin Microbiol Infect* 2007;13:1220-2. <https://doi.org/10.1111/j.1469-0691.2007.01827.x> PMID:17850342
41. Santos RA, Nogueira CS, Granja S, et al. Kawasaki disease and human bocavirus-potential association? <https://doi.org/10.1016/j.jmii.2011.01.016> PMID: 21524620
42. Bajolle F, Meritet JF, Rozenberg F, et al. Markers of a recent bocavirus infection in children with Kawasaki disease: "a year prospective study". *Pathol Biol (Paris)* 2014;62:365-8. <https://doi.org/10.1016/j.patbio.2014.06.002> PMID:25193448
43. Thissen JB, Isshiki M, Jaing C, et al. A novel variant of torque teno virus 7 identified in patients with Kawasaki disease. *PLoS One* 2018;13(12):e0209683.

- <https://doi.org/10.1371/journal.pone.0209683>  
PMid:30592753 PMCID:PMC6310298
44. Maggio MC, Fabiano C, Corsello G. Kawasaki disease triggered by EBV virus in a child with familial Mediterranean fever. *Ital J Pediatr* 2019;45:129.  
<https://doi.org/10.1186/s13052-019-0717-8>  
PMid:31627741 PMCID:PMC6798734
45. Maggio MC, Cimaz R, Alaimo A, et al. Kawasaki disease triggered by parvovirus infection: an atypical case report of two siblings. *J Med Case Rep* 2019;13:104.  
<https://doi.org/10.1186/s13256-019-2028-5>  
PMid:31014402 PMCID:PMC6480815
46. Wang J, Sun F, Deng HL, et al. Influenza A (H1N1) pdm09 virus infection in a patient with incomplete Kawasaki disease: A case report. *Medicine (Baltimore)* 2019;98(15):e15009.  
<https://doi.org/10.1097/MD.00000000000015009>  
PMid:30985646 PMCID:PMC6485757
47. Chang LY, Lu CY, Shao PL, et al. Viral infections associated with Kawasaki disease. *J Formos Med Assoc* 2014;113:148-54.  
<https://doi.org/10.1016/j.jfma.2013.12.008>  
PMid:24495555 PMCID:PMC7125523
48. Esper F, Shapiro ED, Weibel C, et al. Association between a novel human coronavirus and Kawasaki disease. *J Infect Dis* 2005;191:499-502.  
<https://doi.org/10.1086/428291>  
PMid:15655771 PMCID:PMC7199489
49. Dominguez SR, Anderson MS, Glodé MP, et al. Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki syndrome. *J Infect Dis* 2006;194:1697-01.  
<https://doi.org/10.1086/509509>  
PMid:17109341 PMCID:PMC7199878
50. Shirato K, Imada Y, Kawase M, et al. Possible involvement of infection with human coronavirus 229E, but not NL63, in Kawasaki disease. *J Med Virol* 2014;86:2146-53.  
<https://doi.org/10.1002/jmv.23950>  
PMid:24760654 PMCID:PMC7166330
51. Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. *Hosp Pediatr* 2020;10:537-40.  
<https://doi.org/10.1542/hpeds.2020-0123>  
PMid: 32265235
52. Rivera-Figueroa EI, Santos R, Simpson S, et al. Incomplete Kawasaki Disease in a child with Covid-19. *Indian Pediatr* 2020 May 9:S097475591600179. PMid: 32393680
53. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study *Lancet* 2020;395(10239): 1771-8.  
[https://doi.org/10.1016/S0140-6736\(20\)31103-X](https://doi.org/10.1016/S0140-6736(20)31103-X)  
PMid: 32410760
54. Dufort EM, Koumans EH, Chow EJ, et al. Multisystem inflammatory syndrome in children in New York State. *N Engl J Med* 2020 Jun 29.  
<https://doi.org/10.1056/NEJMoa2021756>  
PMid: 32598830
55. Rowley AH, Baker SC, Shulman ST, et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. *PLoS One* 2008;3:e1582.  
<https://doi.org/10.1371/journal.pone.0001582>  
PMid:18270572 PMCID:PMC2216059
56. Rowley AH, Baker SC, Shulman ST, et al. Ultrastructural, immunofluorescence, and RNA evidence support the hypothesis of a "new" virus associated with Kawasaki disease. *J Infect Dis* 2011;203:1021-30.  
<https://doi.org/10.1093/infdis/jiq136>  
PMid:21402552 PMCID:PMC3068030
57. L'Huillier AG, Brito F, Wagner N, et al. Identification of viral signatures using high-throughput sequencing on blood of patients with Kawasaki disease. *Front Pediatr* 2019;7:524.  
<https://doi.org/10.3389/fped.2019.00524>  
PMid:31921732 PMCID:PMC6930886
58. Esposito S, Polinori I, Rigante D. The gut microbiota-host partnership as a potential driver of Kawasaki syndrome. *Front Pediatr* 2019;7:124.  
<https://doi.org/10.3389/fped.2019.00124>  
PMid:31024869 PMCID:PMC6460951
59. Marrani E, Burns JC, Cimaz R. How should we classify Kawasaki disease? *Front Immunol* 2018;9:2974. doi: 10.3389/fimmu.2018.02974.  
<https://doi.org/10.3389/fimmu.2018.02974>  
PMid:30619331 PMCID:PMC6302019
60. Rigante D. A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner. *Expert Rev Clin Immunol* 2017;13:571-97.  
<https://doi.org/10.1080/1744666X.2017.1280396>  
PMid:28064547
61. Rigante D. The broad-ranging panorama of systemic autoinflammatory disorders with specific focus on acute painful symptoms and hematologic manifestations in children. *Mediterr J Hematol Infect Dis* 2018; 10(1): e2018067  
<https://doi.org/10.4084/mjhid.2018.067>  
PMid:30416699 PMCID:PMC6223578
62. Rigante D, Frediani B, Galeazzi M, et al. From the Mediterranean to the sea of Japan: the transcontinental odyssey of autoinflammatory diseases. *Biomed Res Int* 2013;2013:485103  
<https://doi.org/10.1155/2013/485103>  
PMid:23971037 PMCID:PMC3736491